See the DrugPatentWatch profile for Dayvigo
Dayvigo, a medication for insomnia, received approval in Japan in 2021 [1]. It is marketed under the brand name Dayvigo in Japan and is available in 5 mg and 10 mg tablet formulations [2]. The drug is developed by Eisai Co., Ltd. [2].
When is Dayvigo's patent protection expected to end in Japan?
The patent expiry for Dayvigo in Japan is a significant factor for potential generic competition. While specific patent expiry dates can be complex and subject to extensions or challenges, information on patent status for pharmaceuticals can be found through resources like DrugPatentWatch.com [3].
How does Dayvigo work?
Dayvigo is a dual orexin receptor antagonist (DORA). It works by blocking the binding of wake-promoting neuropeptides, orexin A and orexin B, to both the OX1R and OX2R receptors in the brain [1][4]. By inhibiting the orexin signaling system, Dayvigo helps to reduce wakefulness and promote sleep [1].
What are the approved uses for Dayvigo?
In Japan, Dayvigo is approved for the treatment of insomnia [1]. This indication is consistent with its approvals in other major markets [4].
Who is the manufacturer of Dayvigo?
Eisai Co., Ltd. is the company that developed and manufactures Dayvigo [2].
What are the potential side effects of Dayvigo?
Common side effects reported with Dayvigo can include sleep paralysis and hallucinations [1]. Patients and healthcare providers should be aware of these potential adverse events.
How does Dayvigo compare to other insomnia medications?
Dayvigo belongs to a class of drugs known as dual orexin receptor antagonists (DORAs). This mechanism of action differs from older insomnia medications such as benzodiazepines or Z-drugs, which act on GABA receptors. DORAs are designed to target the wakefulness system directly. The efficacy and side effect profiles of DORAs like Dayvigo are distinct from other classes of sleep aids [1][4].
What clinical data supports Dayvigo's use in Japan?
The approval of Dayvigo in Japan was based on clinical trials demonstrating its efficacy and safety [1]. These studies typically assess the drug's ability to improve sleep onset and maintenance compared to placebo [4].
Sources:
[1] https://www.eisai.com/news/2021/pdf/20210122_2.pdf
[2] https://www.eisai.com/news/2021/pdf/20210323.pdf
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-dayvigo-treatment-insomnia